Regeneron Pharmaceuticals Stock Price, News & Analysis (NASDAQ:REGN) $817.56 +8.97 (+1.11%) (As of 10:02 AM ET) Add Compare Share Share Today's Range$810.25▼$818.4150-Day Range$775.18▼$843.6652-Week Range$668.00▼$853.97Volume34,097 shsAverage Volume558,034 shsMarket Capitalization$89.07 billionP/E Ratio23.32Dividend YieldN/APrice Target$903.52 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Regeneron Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside11.7% Upside$903.52 Price TargetShort InterestHealthy1.34% of Float Sold ShortDividend StrengthN/ASustainability-2.69Upright™ Environmental ScoreNews Sentiment1.05Based on 18 Articles This WeekInsider TradingSelling Shares$2.58 M Sold Last QuarterProj. Earnings Growth2.11%From $35.55 to $36.30 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.55 out of 5 starsMedical Sector134th out of 949 stocksPharmaceutical Preparations Industry47th out of 445 stocks 3.3 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 19 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $903.52, Regeneron Pharmaceuticals has a forecasted upside of 11.7% from its current price of $808.59.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.34% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 6.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -2.69. Previous Next 3.9 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Regeneron Pharmaceuticals this week, compared to 11 articles on an average week.Search Interest21 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 425% compared to the previous 30 days.MarketBeat Follows3 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,575,126.00 in company stock.Percentage Held by InsidersOnly 8.83% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions84.15% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 2.11% in the coming year, from $35.55 to $36.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 23.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.32.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 23.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 86.11.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 3.02. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 3.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More REGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REGN Stock News HeadlinesNovember 30, 2023 | americanbankingnews.comJefferies Financial Group Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $937.00November 29, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Receives "Buy" Rating from Truist FinancialNovember 30, 2023 | Tomorrow Investor (Ad)Why Microsoft Just Placed A Huge Bet On NuclearEven with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.November 28, 2023 | markets.businessinsider.com11 Analysts Have This to Say About Regeneron PharmaceuticalsNovember 28, 2023 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 35th Annual Healthcare Conference (Transcript)November 27, 2023 | finance.yahoo.comDupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious DiseaseNovember 24, 2023 | finance.yahoo.comKiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's HowNovember 24, 2023 | finance.yahoo.comRegeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?November 30, 2023 | Tomorrow Investor (Ad)Why Microsoft Just Placed A Huge Bet On NuclearEven with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.November 15, 2023 | finance.yahoo.comRegeneron Announces Investor Conference PresentationNovember 15, 2023 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference (Transcript)November 13, 2023 | finance.yahoo.comRegeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)November 11, 2023 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Presents at Truist Securities BioPharma Symposium (Transcript)November 11, 2023 | seekingalpha.comRegeneron Pharmaceuticals Inc. (REGN) UBS Biopharma Conference (Transcript)November 11, 2023 | finance.yahoo.comHere's Why Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt ResponsiblyNovember 9, 2023 | msn.comDeutsche Bank Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Hold RecommendationNovember 8, 2023 | finance.yahoo.comRegeneron Pharmaceuticals (REGN): Bronte Capital’s Biggest Winner of This QuarterNovember 7, 2023 | finance.yahoo.comRegeneron Pharmaceuticals' (NASDAQ:REGN) 19% CAGR outpaced the company's earnings growth over the same five-year periodNovember 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Zoetis (ZTS), Moderna (MRNA) and Regeneron (REGN)November 3, 2023 | msn.comRegeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst ReviewNovember 3, 2023 | seekingalpha.comRegeneron: Analysis Of Vabysmo's Impact On Eylea FranchiseNovember 3, 2023 | msn.comRegeneron raised to Outperform at Raymond James on Q3 resultsNovember 3, 2023 | finance.yahoo.comRegeneron Is Pointed Higher, But Here's the Price Where I'd Be a BuyerNovember 3, 2023 | finance.yahoo.comMorning Brew: Jobs Growth Moderates, Fortinet Plunges, Apple Dips, and Regeneron UpgradedNovember 3, 2023 | finance.yahoo.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2023 Earnings Call TranscriptNovember 3, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: United Therapeutics (UTHR), Regeneron (REGN)November 3, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Regeneron (REGN)See More Headlines Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees11,851Year Founded1988Price Target and Rating Average Stock Price Target$903.52 High Stock Price Target$1,050.00 Low Stock Price Target$680.00 Potential Upside/Downside+11.7%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage26 Analysts Profitability EPS (Most Recent Fiscal Year)$35.06 Trailing P/E Ratio23.06 Forward P/E Ratio22.75 P/E Growth3.01Net Income$4.34 billion Net Margins30.47% Pretax Margin33.42% Return on Equity18.61% Return on Assets14.49% Debt Debt-to-Equity Ratio0.11 Current Ratio5.18 Quick Ratio4.47 Sales & Book Value Annual Sales$12.17 billion Price / Sales7.24 Cash Flow$45.12 per share Price / Cash Flow17.92 Book Value$228.59 per share Price / Book3.54Miscellaneous Outstanding Shares108,950,000Free Float99,327,000Market Cap$88.10 billion OptionableOptionable Beta0.13 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Leonard S. Schleifer M.D. (Age 70)Ph.D., Co-Founder, President, CEO & Co-Chairman Comp: $7MDr. George D. Yancopoulos M.D. (Age 63)Ph.D., Co-Founder, President, Chief Scientific Officer & Co-Chairman Comp: $6.59MMr. Robert E. Landry Jr. (Age 59)Executive VP of Finance & CFO Comp: $1.84MDr. Andrew J. Murphy Ph.D. (Age 64)Executive Vice President of Research Comp: $1.62MMr. Daniel P. Van Plew (Age 50)Executive VP and GM of Industrial Operations & Product Supply Comp: $1.95MMs. Marion E. McCourt (Age 63)Executive Vice President of Commercial Comp: $1.5MMs. Patrice GiloolySenior Vice President of Quality Assurance & OperationsMr. Christopher R. Fenimore CPA (Age 52)Senior VP, Head of Accounting & Controller Mr. Gerald UnderwoodSenior Vice President of Technical OperationsMr. Bob McCowanSenior VP of IT & Chief Information OfficerMore ExecutivesKey CompetitorsVertex PharmaceuticalsNASDAQ:VRTXBristol-Myers SquibbNYSE:BMYGSKNYSE:GSKSanofiNASDAQ:SNYTakeda PharmaceuticalNYSE:TAKView All CompetitorsInsiders & InstitutionsIMA Wealth Inc.Sold 44 shares on 11/28/2023Ownership: 0.003%ASB Consultores LLCSold 146 shares on 11/28/2023Ownership: 0.000%USA Financial FormulasSold 17 shares on 11/27/2023Ownership: 0.002%Banque Pictet & Cie SASold 1,772 shares on 11/27/2023Ownership: 0.001%AllSquare Wealth Management LLCBought 26 shares on 11/27/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Regeneron Pharmaceuticals was last updated on Tuesday, November 28, 2023 at 10:48 PM. Pros Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.: Regeneron Pharmaceuticals, Inc. is a global company that discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. Regeneron Pharmaceuticals, Inc. has a strong track record of successful research and development, with a focus on innovative treatments and therapies. Recent developments in Regeneron Pharmaceuticals, Inc.'s pipeline show promising potential for new drugs and treatments. Regeneron Pharmaceuticals, Inc. has established partnerships with reputable organizations, such as the U.S. Biomedical Advanced Research Development Authority and AstraZeneca PLC. Investing in Regeneron Pharmaceuticals, Inc. provides an opportunity to support advancements in medical science and contribute to improving healthcare worldwide. Cons Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons: The stock price of Regeneron Pharmaceuticals, Inc. is subject to market fluctuations and may not always reflect the company's true value. As with any pharmaceutical company, there are risks associated with the success of drug development and regulatory approvals. Competition in the pharmaceutical industry is intense, and Regeneron Pharmaceuticals, Inc. may face challenges from other companies with similar products or treatments. Changes in healthcare policies and regulations can impact the profitability and market demand for Regeneron Pharmaceuticals, Inc.'s products. Investing in the pharmaceutical industry requires careful consideration of the potential risks and rewards, as well as a long-term investment perspective. REGN Stock Analysis - Frequently Asked Questions Should I buy or sell Regeneron Pharmaceuticals stock right now? 26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" REGN shares. View REGN analyst ratings or view top-rated stocks. What is Regeneron Pharmaceuticals' stock price target for 2024? 26 equities research analysts have issued 12-month target prices for Regeneron Pharmaceuticals' stock. Their REGN share price targets range from $680.00 to $1,050.00. On average, they expect the company's share price to reach $903.52 in the next year. This suggests a possible upside of 11.7% from the stock's current price. View analysts price targets for REGN or view top-rated stocks among Wall Street analysts. How have REGN shares performed in 2023? Regeneron Pharmaceuticals' stock was trading at $721.49 on January 1st, 2023. Since then, REGN shares have increased by 12.1% and is now trading at $808.59. View the best growth stocks for 2023 here. When is Regeneron Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, February 2nd 2024. View our REGN earnings forecast. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Thursday, November, 2nd. The biopharmaceutical company reported $10.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.39 by $0.78. The biopharmaceutical company had revenue of $3.36 billion for the quarter, compared to analyst estimates of $3.23 billion. Regeneron Pharmaceuticals had a net margin of 30.47% and a trailing twelve-month return on equity of 18.61%. Regeneron Pharmaceuticals's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $9.98 EPS. Read the conference call transcript. What ETFs hold Regeneron Pharmaceuticals' stock? ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA), American CenturyFocused Dynamic Growth ETF (FDG) and Subversive Mental Health ETF (SANE). What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM). Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (9.03%), Loomis Sayles & Co. L P (1.14%), Northern Trust Corp (0.98%), Morgan Stanley (0.89%), Bank of New York Mellon Corp (0.89%) and Legal & General Group Plc (0.75%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.Read More This page (NASDAQ:REGN) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.